Analysis of internal exposure of staff performing 131I treatment in radiodiagnosis and radiotherapy institutions in China
10.3760/cma.j.cn112271-20240729-00286
- VernacularTitle:我国放射诊疗机构 131I治疗开展情况与工作人员内照射水平分析
- Author:
Xiaoliang LI
1
;
Quanfu SUN
;
Fei TUO
;
Weihong CHEN
;
Keyi LU
;
Jianfeng ZHANG
;
Jianxiang LIU
Author Information
1. 中国疾病预防控制中心辐射防护与核安全医学所 辐射防护与核应急中国疾病预防控制中心重点实验室，北京 100088
- Publication Type:Journal Article
- Keywords:
Individual monitoring;
Internal exposure;
131I;
Nuclear medicine
- From:
Chinese Journal of Radiological Medicine and Protection
2025;45(6):506-511
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To investigate the number of medical institutions and staff involved in 131I diagnosis and therapy in China, and to ascertain the level of 131I activity incorporated in thyroid of medical staff performing the 131I treatment. Methods:Questionnaires were used to investigate the basic information on nuclear medicine practices in all the non-military hospitals in China. Portable gamma spectrometers were used to determine and analyze the 131I activity in thyroid of the medical staff in some radioiodine treatment workplaces. The result were reported through National Radiological Health Information Platform. Results:Until December 2022, there had been 959 hospitals performing clinical nuclear medicine practices in China, with a total of 10 820 medical staff. In China, there have been 623 hospitals performing 131I therapeutical procedures, accounting for 65.0% of all nuclear medicine hospitals, and 333 hospitals performing 131I treatment of thyroid cancer, accounting for 34.7%. The hospitals equipped with automated radiopharmaceutical dispenser accounted for 61.3% of the 623 hospitals. A total of 2 210 nuclear medicine staff were monitored for internal exposure in 20 provinces in 2022, with 249 (11.3%) having activities above 100 Bq and the maximum value of 2.9 × 10 4 Bq. A total of 426 nuclear medicine staff in four provinces were detected using HPGe detectors, with 101 (23.7%) detected to have 131I in their thyroid glands. A total of 1 748 in 17 provinces were detected using NaI or LaBr detectors, with 379 (21.2%) detected to have 131I in their thyroid glands. The detection rate of 131I in the staff was found to increase with the increased amount of 131I purchased by hospitals. The detection rate of 131I in the hosptitals having purchased the amount of 131I≥3.70 × 10 6 MBq in 2021 was 32.1%. This value was notably higher than in the other three groups whose purchased amount <3.70 × 10 6 MBq, with a statistically significant difference( χ2=15.46, P < 0.001). Conclusions:There were great differences in the number of both hospitals and staff performing 131I treatment between different provinces in China. About one fifth of the staff in the 131I treatment workplaces could be detected to have incorporated 131I in their thyroid glands.
